Drug Profile
Lesinurad - AstraZeneca
Alternative Names: RDEA-594; RDEA594 sodium; ZurampicLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ardea Biosciences
- Developer Ardea Biosciences; Grunenthal; Ironwood Pharmaceuticals
- Class Acetic acids; Antigouts; Cyclopropanes; Naphthalenes; Small molecules; Sulfides; Triazoles; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gout; Hyperuricaemia
Most Recent Events
- 04 May 2021 Discontinued - Phase-III for Hyperuricaemia (Adjunctive treatment, Combination therapy) in Ukraine (PO)
- 23 Feb 2021 No development reported - Phase-III for Hyperuricaemia (Adjunctive treatment, Combination therapy) in Ukraine (PO)
- 04 Sep 2019 AstraZeneca plans an observational post-authorization study in Gout and Hyperuricaemia in USA, Italy and Spain (SATURATES) (NCT04072471)